Auditory-Cognitive Dual-Task Intervention for Older Adults With Hearing Loss
1 other identifier
interventional
60
1 country
1
Brief Summary
Background: Age-related hearing loss (ARHL) is a common and irreversible condition that has been recently associated with cognitive decline and dementia. Hence, if ARHL is treated earlier, the risk of dementia might decrease. However, in China, only 0.8% of older adults with hearing loss wore hearing aids, and over two-thirds (67.5%) of older adults with ARHL in Hong Kong had either been formally diagnosed or treated. There is also limited information on the feasibility and efficacy of hearing loss interventions for older people in Hong Kong. It is important to develop hearing loss interventions that have the potential to improve cognitive functions among older people. Aims: This study aims to assess the feasibility and acceptability of a new auditory-cognitive dual-task intervention (ACDT) for community-dwelling older adults with hearing loss, and to examine the preliminary efficacy of ACDT on their cognitive function. Study design and Methods: This is mixed-model design, using a 2-arm, parallel-group, single-blinded, pilot randomized controlled trial (pilot RCT). A total of 60 community-dwelling older adults in Hong Kong who have mild to moderate hearing loss and normal cognitive performance will be recruited. Participants will be randomly assigned to the auditory-cognitive dual-task intervention group (ACDTG), and control group with no specific intervention (a "wait list" group) (CG). Each ACDTG participant will receive the intervention for 12 weeks (5 days x 60-min sessions per day). All participants in all groups will be assessed for cognitive function (primary outcome), social isolation, and loneliness, and hearing at baseline (T0), and after the intervention (T1). Post-intervention interviews will be conducted to obtain perspectives of participants in the ACDTG on the feasibility and acceptability of the ACDT intervention. Data analysis: Participant characteristics and outcome variables will be analysed through descriptive statistics. Differences in cognition score and other outcomes across time points among the participant groups will be measured by Generalized Estimating Equations (GEE). The statistical software package IBM SPSS version 26.0 will be used. Content analysis will used to analyse the post-intervention interviews. Expected results: ACDT will be feasible for implementation and acceptable for community-dwelling older adults with hearing loss. While ACDT will not be able to improve underlying hearing in ARHL, it will be more effective on improving participants' cognitive function, social engagement and loneliness, and ability in information processing, interpretation and communication, than CG.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 18, 2024
CompletedFirst Posted
Study publicly available on registry
July 3, 2024
CompletedStudy Start
First participant enrolled
August 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2025
CompletedJuly 18, 2025
June 1, 2024
11 months
June 18, 2024
July 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Global cognition
Global cognition will be measured by the Hong Kong-Montreal Cognitive Assessment (HK-MoCA). MoCA measures multiple cognitive domains, including attention, orientation, concentration, language, memory, executive functions and visuo-spatial skills. MoCA ≥26 is considered as normal, while 22-26 refers to mild cognitive impairment.
will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)
Secondary Outcomes (10)
Learning and memory
will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)
Hearing
will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)
Social isolation
will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)
Loneliness
will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)
Hearing
will be assessed at baseline (T0), and Week 12 (immediately after the intervention) (T1)
- +5 more secondary outcomes
Study Arms (2)
Auditory-cognitive dual-task training (ACDT)
EXPERIMENTALThe new auditory-cognitive dual-task training (ACDT) is a 12-week program (5 times/week, 60 minutes per day). Auditory training (i.e., speech-in-noise training, rapid speech training and competing speaking training) will be incorporated with cognitive exercises involving the domains of executive function, perceptual-motor ability, memory, and complex attention.
Control
NO INTERVENTIONno specific treatment. This is a "wait list" group, participants can choose either the Auditory-cognitive dual-task training or the cognitive training after 12 weeks.
Interventions
The components of auditory training are designed based on an auditory training and aural rehabilitation program LACETM (Listening \& Communication Enhancement) developed by our study team member. The cognitive training was developed and tested feasible and valid in our study team's previous dual-task Zumba cognitive training.
Eligibility Criteria
You may qualify if:
- aged 60 and above living in the community;
- have mild to moderate hearing loss with a pure-tone average (PTA) between 25 and 60 dB in both ears (average hearing threshold at 0.5, 1, 2, and 4 kHz measuring by audiometer with headphones in a quite listening environment, no hearing aid use within the past 6 months;
- with normal cognitive performance (MoCA score ≥26); and
- are willing to and capable of providing informed consent and complying with study procedures.
You may not qualify if:
- have a history of psychosis, mania, bipolar disorder, substance use disorder or have current suicidal ideation;
- with severe or unstable medical illness, significant retrocochlear pathology or organic lesion responsible for hearing loss;
- a diagnosis of probable Alzheimer's disease, vascular dementia, FTD, or Parkinson's Disease; and
- taking medications such as antidepressants, sedatives, or antiepileptics that may affect cognition.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
PolyU
Hong Kong, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ivy Zhao, Dr
School of Nursing, the Hong Kong Polytechnic University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 18, 2024
First Posted
July 3, 2024
Study Start
August 1, 2024
Primary Completion
June 30, 2025
Study Completion
July 1, 2025
Last Updated
July 18, 2025
Record last verified: 2024-06
Data Sharing
- IPD Sharing
- Will share
Individual deidentified participant data (including data dictionaries) will be shared. The investigators will publish research findings in peer reviewed and international official journals without Individual identifiable participant information according to the ethical requirement. Individual deidentified participant dataset can be shared per request and approved by the research core team.